Tirzepatide: 20.2% in SURMOUNT-5 In the head-to-head SURMOUNT-5 trial, tirzepatide reached 20.2% average weight loss compared with 13.7% for semaglutide at 72 weeks
What Makes Tirzepatide Different That second pathway is the main mechanical difference
The result is a dry powder or cake that contains the peptide in a stable, dehydrated form
Evidence boundary No human or animal trial has tested retatrutide and MOTS-c together
Limited coverage exists under specific employer-, plan-, and diagnosis-based conditions: Some employer and government plans offer coverage with prior authorization Coverage varies by employer, plan type, and diagnosis BCBS operates through independent state affiliates, so rules differ by state Who this guide is for BCBS members exploring Zepbound coverage through employer-sponsored plans, ACA marketplace plans, Medicare Advantage, or the Federal Employee Program (FEP)
Understanding how Wegovy works and its safety profile helps patients make informed decisions about their treatment and avoid unnecessary concerns about medication interactions